Scarica l'app Stockscreener
12.11
3.11%
0.365
Dopo l'orario di chiusura:
12.09
-0.02
-0.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVCR Giù?
Forum
Previsione
Precedente Chiudi:
$11.74
Aprire:
$11.85
Volume 24 ore:
2.25M
Relative Volume:
1.34
Capitalizzazione di mercato:
$1.36B
Reddito:
$577.74M
Utile/perdita netta:
$-149.78M
Rapporto P/E:
-8.65
EPS:
-1.4
Flusso di cassa netto:
$-78.21M
1 W Prestazione:
-5.46%
1M Prestazione:
+4.31%
6M Prestazione:
-26.38%
1 anno Prestazione:
-54.47%
Intervallo 1D:
$11.74
$12.21
Intervallo di 1 settimana:
$10.79
$12.57
Portata 52W:
$10.70
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Nome
Novocure Ltd
Settore
Industria
Telefono
44 (0)15 3475 6700
Indirizzo
NO. 4 THE FORUM, ST. HELIER
Confronta NVCR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.11 | 1.32B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
125.08 | 218.05B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.52 | 144.86B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
364.02 | 139.34B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.36 | 130.75B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.19 | 49.78B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Iniziato | Ladenburg Thalmann | Buy |
| 2024-12-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-28 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Iniziato | SVB Securities | Outperform |
| 2023-07-31 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2023-05-16 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Reiterato | H.C. Wainwright | Buy |
| 2022-11-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Downgrade | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-08 | Iniziato | Loop Capital | Buy |
| 2022-02-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2022-01-03 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-14 | Downgrade | Wedbush | Neutral → Underperform |
| 2021-01-25 | Reiterato | Piper Sandler | Overweight |
| 2020-09-23 | Iniziato | Northland Capital | Outperform |
| 2020-09-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Downgrade | Truist | Buy → Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Perform |
| 2020-05-01 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Aggiornamento | SunTrust | Hold → Buy |
| 2019-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2018-11-02 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Iniziato | Evercore ISI | Outperform |
| 2018-04-18 | Reiterato | Mizuho | Buy |
| 2018-02-23 | Reiterato | Mizuho | Buy |
| 2017-05-24 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Reiterato | Wedbush | Outperform |
| 2016-01-19 | Iniziato | Barclays | Underweight |
| 2015-12-02 | Iniziato | Deutsche Bank | Hold |
Mostra tutto
Novocure Ltd Borsa (NVCR) Ultime notizie
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
NovoCure (NASDAQ:NVCR) Stock Price Up 7%Time to Buy? - MarketBeat
What is the fair value estimate for NovoCure Limited (038) stock in 2025Weekly Trade Report & Verified Stock Trade Ideas - Newser
Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025? - Yahoo Finance UK
NovoCure Limited $NVCR Shares Purchased by American Century Companies Inc. - MarketBeat
NovoCure stock rating reiterated at Buy by H.C. Wainwright amid CEO change - Investing.com Nigeria
Can NovoCure's Tumor Treating Fields Redefine Cancer Care By 2026? - RTTNews
Novocure names Frank Leonard as new CEO, replacing Ashley Cordova By Investing.com - Investing.com Australia
How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm - simplywall.st
Novocure CEO Ashley Cordova resigns, Frank Leonard succeeds - TipRanks
Novocure (NVCR) Appoints New CEO Amid Leadership Change - GuruFocus
Novocure (NASDAQ: NVCR) elevates President Frank Leonard to CEO as Ashley Cordova resigns - Stock Titan
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN
Novocure (NASDAQ: NVCR) to Present at 37th Piper Sandler Healthcare Conference on Dec. 2 - Stock Titan
NovoCure Limited (NVCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will NovoCure Limited stock attract more institutional investorsInsider Buying & Breakout Confirmation Trade Signals - newser.com
Novocure at Jefferies London: Expanding Horizons in Cancer Treatment By Investing.com - Investing.com South Africa
Tangible book value per share of NovoCure Ltd. – DUS:038 - TradingView
Published on: 2025-11-19 05:31:32 - newser.com
Will NovoCure Limited stock benefit from green energy trendsPrice Action & AI Forecasted Entry/Exit Points - newser.com
NovoCure Limited (NVCR) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Using flow based indicators on NovoCure LimitedTrade Performance Summary & Safe Entry Zone Identification - newser.com
Why NovoCure Limited (038) stock could rally strongly2025 Analyst Calls & Weekly Watchlist of Top Performers - newser.com
How interest rate cuts could boost NovoCure Limited stockWeekly Gains Summary & Verified Entry Point Signals - newser.com
What sentiment indicators say about NovoCure Limited stockMarket Risk Report & Verified Short-Term Plans - newser.com
Can NovoCure Limited stock deliver sustainable ROEEarnings Beat & Risk Managed Investment Entry Signals - newser.com
NovoCure (NVCR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Published on: 2025-11-14 04:19:47 - newser.com
Should Rising Losses Despite Higher Sales Require Action From NovoCure (NVCR) Investors? - simplywall.st
NVCR (NovoCure) ROA % : -11.44% (As of Sep. 2025) - GuruFocus
2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - Yahoo Finance
Novocure (NASDAQ: NVCR) at Jefferies Healthcare, 2:00 p.m. GMT; webcast, 14-day replay - Stock Titan
NovoCure (NVCR): Assessing Valuation Following Q3 Sales Growth and Rising Net Losses - simplywall.st
Novocure stock hits 52-week low at 10.82 USD By Investing.com - Investing.com Australia
Novocure stock hits 52-week low at 10.82 USD - Investing.com
Can NovoCure Limited hit a new high this monthM&A Rumor & Fast Entry High Yield Stock Tips - newser.com
Can momentum traders help lift NovoCure LimitedMarket Trend Report & Reliable Intraday Trade Plans - newser.com
Oversold Conditions For NovoCure (NVCR) - Nasdaq
[Form 4] NovoCure Ltd Insider Trading Activity - Stock Titan
Novocure Ltd. Reports Q3 2025 Financial Results - MSN
Novocure Ltd Azioni (NVCR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novocure Ltd Azioni (NVCR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
3.78%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):